Overview
Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against disc herniation. Stayble currently conducts a phase 1b within disc herniation.
LATEST PRESS RELEASES
(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2
EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA,...
Abstract on the effect of STA363 on disc volume from the phase 1b study has been accepted for oral presentation at a major international congress
Stayble Therapeutics AB ("Stayble" or "the Company") announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar...